Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;33(3):762-808.
doi: 10.1038/s41375-018-0277-8. Epub 2018 Oct 5.

Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2

Olivier Humbert #  1 , George S Laszlo #  2 , Sophie Sichel  2 , Christina Ironside  2 , Kevin G Haworth  2 , Olivia M Bates  2 , Mary E Beddoe  2 , Ray R Carrillo  2 , Hans-Peter Kiem #  2   3 , Roland B Walter #  2   4
Affiliations

Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2

Olivier Humbert et al. Leukemia. 2019 Mar.
No abstract available

PubMed Disclaimer

References

    1. Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119:6198–208. - DOI
    1. Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014;28:143–53. - DOI
    1. Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017;31:1855–68. - DOI
    1. Walter RB. Investigational CD33-targeted therapeutics for acute myeloid leukemia. Expert Opin Investig Drugs. 2018;27:339–48. - DOI
    1. Brinkman-Van der Linden EC, Angata T, Reynolds SA, Powell LD, Hedrick SM, Varki A. CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice. Mol Cell Biol. 2003;23:4199–206. - DOI

Publication types

MeSH terms

Substances

LinkOut - more resources